Home > Cloud PRWire > Neural Therapeutics – How do we prevent people getting addicted to opioids?

Neural Therapeutics – How do we prevent people getting addicted to opioids?

–News Direct–

Neural Therapeutics CEO Ian Campbell is answering some of the questions raised by Scientific Advisor Professor David Nutt's presentation on the potentially revolutionary untapped effects of psychedelic medicine.

Today's questions asks: "The opioid crisis has touched every sector of society and shows no sign of stopping. How do we prevent more people from becoming addicted?"

He emphasised that contrary to common concerns, the substances developed by the company have not shown addictive properties in clinical trials. Campbell highlighted that there is no evidence of withdrawal symptoms in patients. Moreover, ongoing scientific work supports the effectiveness of these substances in treating individuals with substance use disorders.

The presentation focused on what Professor Nutt describes as the utility of psychedelic compounds and their potential to transform the treatment of mental illness.

To watch the full presentation, click here: https://www.proactiveinvestors.co.uk/companies/news/1035785/professor-david-nutt-presents-his-insights-into-psychedelic-medicine-neural-therapeutics-1035785.html

Neural Therapeutics is a drug-discovery company focusing on plant-based active substances with the goal of delivering beneficial, over-the-counter dietary supplements and psychedelic-based therapeutic medicines to treat serious mental ailments where no significant treatment is available today.

Contact Details

Proactive United States

+1 347-449-0879

[email protected]

View source version on newsdirect.com: https://newsdirect.com/news/neural-therapeutics-how-do-we-prevent-people-getting-addicted-to-opioids-247860378

Neural Therapeutics Inc.

comtex tracking


Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Sahyadri Times journalist was involved in the writing and production of this article.